Dubai Law No. 17 of 2026: Establishing the Dubai Longevity Authority and Shaping the Future of Healthy Ageing
Introduction
Dubai has taken another significant step towards becoming a global leader in innovation by enacting Dubai Law No. 17 of 2026, establishing the Dubai Longevity Authority (DLA). The legislation reflects the Emirate’s commitment to promoting healthy ageing, advancing preventive healthcare, supporting scientific research, and attracting international investment in one of the world’s fastest-growing healthcare sectors.
With increasing life expectancy and rising demand for preventive medicine and age-management solutions, longevity has become a strategic economic and healthcare priority worldwide. Dubai’s new legal framework seeks to position the Emirate at the forefront of this emerging industry.
Why Longevity Matters
Longevity is no longer simply about extending life expectancy. Modern longevity science focuses on extending healthy life expectancy—the number of years individuals remain active, productive, and free from chronic disease.
Advances in artificial intelligence, genomics, precision medicine, regenerative therapies, biotechnology, wearable health technology, and predictive diagnostics are transforming healthcare from a reactive system into one centred on prevention and early intervention.
Recognising these global trends, Dubai has established a dedicated authority to coordinate policies, regulation, investment, and innovation in this rapidly evolving field.
Establishment of the Dubai Longevity Authority
Dubai Law No. 17 of 2026 creates the Dubai Longevity Authority as a specialised government entity responsible for developing and implementing the Emirate’s longevity strategy.
The Authority is expected to work closely with healthcare regulators, government agencies, research institutions, universities, private healthcare providers, and international organisations to build a comprehensive longevity ecosystem.
Its mandate extends beyond healthcare regulation and encompasses economic development, scientific research, investment promotion, and international collaboration.
Objectives of the Law
The principal objectives of the legislation include:
- Promoting healthy ageing across all segments of society.
- Supporting scientific research into longevity and age-related diseases.
- Developing policies for preventive healthcare.
- Encouraging innovation in biotechnology and regenerative medicine.
- Attracting local and foreign investment into longevity-related industries.
- Positioning Dubai as a global destination for longevity medicine and wellness tourism.
- Encouraging collaboration between government, academia, and the private sector.
- Enhancing quality of life while reducing long-term healthcare costs.
These objectives align closely with Dubai’s broader economic diversification strategy and its ambition to become one of the world’s leading centres for innovation.
Powers and Responsibilities of the Authority
Dubai Law No. 17 of 2026 grants the Authority broad responsibilities, including:
Strategic Planning
The Authority will formulate Dubai’s long-term strategy for longevity and healthy ageing, ensuring coordination among relevant government entities.
Policy Development
It will recommend new legislation, regulatory policies, and technical standards governing longevity-related activities.
Regulatory Oversight
The Authority will develop governance frameworks for longevity services and coordinate with existing healthcare regulators where licensing or supervision is required.
Research and Innovation
Supporting research institutions, encouraging clinical innovation, and facilitating scientific collaboration are central aspects of its mandate.
Investment Promotion
The Authority will actively promote investment opportunities within the longevity sector, helping attract biotechnology companies, medical technology firms, research centres, venture capital, and international healthcare providers.
International Cooperation
The legislation authorises cooperation with foreign governments, international organisations, universities, and research institutions to accelerate scientific progress and knowledge exchange.
Opportunities for Investors
Dubai Law No. 17 of 2026 creates significant opportunities for investors operating in:
- Biotechnology
- Artificial intelligence in healthcare
- Precision medicine
- Genetic testing
- Preventive healthcare
- Medical technology
- Regenerative medicine
- Wellness and rehabilitation
- Digital health platforms
- Medical tourism
- Pharmaceutical innovation
- Longevity clinics
Dubai’s business-friendly regulatory environment, modern infrastructure, strategic geographic location, and strong intellectual property framework are likely to make the Emirate an attractive jurisdiction for international companies seeking regional expansion.
Implications for Healthcare Providers
Healthcare providers should anticipate the gradual introduction of new regulatory standards relating to longevity medicine and preventive healthcare.
Hospitals, specialist clinics, diagnostic laboratories, rehabilitation centres, and medical professionals may increasingly integrate longevity-focused services such as:
- Early disease detection
- Lifestyle medicine
- Preventive screening programmes
- Personalised health management
- Genomic medicine
- Nutritional optimisation
- Biomarker monitoring
- Regenerative therapies
As the sector develops, healthcare providers should closely monitor future executive regulations that may introduce licensing requirements, technical standards, accreditation systems, or operational guidelines.
Medical Tourism
Dubai has already established itself as one of the Middle East’s leading medical tourism destinations.
The new legislation is expected to strengthen this position by encouraging the development of specialised longevity centres capable of attracting international patients seeking advanced preventive healthcare and personalised medical treatments.
This may further diversify Dubai’s healthcare economy while enhancing its global reputation for medical excellence.
Potential Future Regulations
Although Dubai Law No. 17 of 2026 establishes the institutional framework, many operational aspects are likely to be addressed through future executive decisions and implementing regulations.
Areas that may be regulated include:
- Licensing of longevity clinics.
- Professional qualifications.
- Clinical practice standards.
- Ethical use of artificial intelligence.
- Genetic data governance.
- Patient privacy.
- Research ethics.
- Cross-border healthcare services.
- Public-private partnerships.
- Investment incentives.
Businesses intending to enter this sector should remain attentive to these developments.
Legal Considerations
The growth of longevity medicine raises a number of legal issues that organisations should proactively address, including:
- Regulatory compliance.
- Medical malpractice exposure.
- Patient consent.
- Data protection.
- Cybersecurity.
- Intellectual property.
- Clinical research governance.
- Cross-border transfer of health information.
- Commercial agreements.
- Insurance coverage.
- Corporate structuring for healthcare investments.
Obtaining specialist legal advice at an early stage can assist investors and healthcare providers in navigating this evolving regulatory landscape.
Conclusion
Dubai Law No. 17 of 2026 represents an important milestone in the Emirate’s healthcare and economic development strategy. By establishing the Dubai Longevity Authority, Dubai has demonstrated its intention to become a global leader in longevity science, preventive medicine, biotechnology, and healthy ageing.
While the law primarily establishes the institutional framework, it also lays the foundation for substantial future regulatory development and commercial opportunity. Investors, healthcare providers, technology companies, research institutions, and international organisations should closely monitor forthcoming executive regulations as Dubai continues to build one of the world’s most advanced longevity ecosystems.
Disclaimer: This article is provided for general informational purposes only and does not constitute legal advice. The implementation of Dubai Law No. 17 of 2026 will continue to evolve through executive decisions, regulations, and administrative guidance. Businesses and healthcare providers should obtain professional legal advice tailored to their specific circumstances before undertaking activities regulated by the new framework.
For any queries or services regarding legal matters in the UAE, you can contact us at (+971) 4 3298711, or send us an email at proconsult@uaeahead.com, or reach out to us via our Contact Form Page and our dedicated legal team will be happy to assist you. Also visit our website https://uaeahead.com
Article by ProConsult Advocates & Legal Consultants, the Leading Dubai Law Firm providing full legal services & legal representation in UAE courts.
